Live
- Aid group resumes activities at famine-hit camp in Sudan
- Kishan Reddy Vows to End BRS and Congress Influence in Telangana, Criticizes CM's Governance
- Punjab bypolls: Bittu twisting words for political gains, says Congress nominee
- Punjab CM to administer oath to over 10,000 sarpanches on Friday
- BJP Core Committee Plans Protests Against State Government’s Failures
- Mulugu Collector Divakar's Facebook Hacked Again, Cyber Criminals Send Fraudulent Messages Asking for Money
- The Role of Genetics in Obesity: Can Metabolic Bariatric Surgery Help?
- Deputy CM Bhatti Vikramarka's Visit to Khammam District: Lays Foundation for Road Works Worth Rs. 8.9 Crore
- ED Files Charge Sheet in Agrigold Case, Attaches Assets Worth Over ₹4,100 Crores
- Mushfiqur Rahim ruled out of Afghanistan ODIs with finger fracture
Aurobindo unit's Andhra plant receives 1 observation from USFDA after inspection
Aurobindo Pharma Ltd
Aurobindo Pharma on Wednesday said the US health regulator has issued a Form 483 with one observation after inspecting a formulation production facility of its unit in Andhra Pradesh.
New Delhi: Aurobindo Pharma on Wednesday said the US health regulator has issued a Form 483 with one observation after inspecting a formulation production facility of its unit in Andhra Pradesh. The US Food and Drug Administration (US FDA) inspected the Unit IV of APL Healthcare Ltd, a wholly-owned subsidiary of the company, in Tirupati district of Andhra Pradesh from September 13-19, 2023, the Hyderabad-based drug major said in a regulatory filing.
At the end of the inspection, a Form 483 was issued with one observation which is procedural in nature, it added. "We will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest," Aurobindo Pharma stated. As per the USFDA a Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. Shares of Aurobindo Pharma were trading 0.63 per cent down at Rs 889.15 apiece on the BSE.
